Infliximab biosimilar - Pfizer

Drug Profile

Infliximab biosimilar - Pfizer

Alternative Names: Infliximab-Pfizer; PF-06438179; PF-6438179

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rheumatoid arthritis

Most Recent Events

  • 01 Jun 2017 Pfizer completes a phase-III trials in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in USA, Poland, Lithuania, Hungary, Australia, Bosnia-Herzegovina, Brazil, Bulgaria, Canada, Czech Republic, Georgia, Guatemala, Germany, Israel, Japan, Jordan, South Korea, Mexico, Morocco, Peru, Philippines, Romania, Russia, Serbia, South Africa, Tunisia, Ukraine, France, United Kingdom (IV) (NCT02222493) (EudraCT2013-004148-49)
  • 31 May 2017 Preregistration for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in European Union before May 2017 (IV)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top